Zomedica Pharmaceuticals Corp Stock Buy Hold or Sell Recommendation
| ZOM Stock | USD 0.13 0.01 7.14% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Zomedica Pharmaceuticals Corp is 'Strong Sell'. Macroaxis provides Zomedica Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ZOM positions. The advice algorithm takes into account all of Zomedica Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Zomedica Pharmaceuticals' buy or sell advice are summarized below:
Real Value 1.59 | Target Price 6 | Hype Value 0.13 | Market Value 0.13 | Naive Value 0.12 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Zomedica Pharmaceuticals Corp given historical horizon and risk tolerance towards Zomedica Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Zomedica Pharmaceuticals Corp, the advice is generated through an automated system that utilizes algorithms and statistical models.
Zomedica |
Execute Zomedica Pharmaceuticals Buy or Sell Advice
The Zomedica recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Zomedica Pharmaceuticals Corp. Macroaxis does not own or have any residual interests in Zomedica Pharmaceuticals Corp or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Zomedica Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Strong Sell | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Zomedica Pharmaceuticals Trading Alerts and Improvement Suggestions
| Zomedica Pharmaceuticals had very high historical volatility over the last 90 days | |
| Zomedica Pharmaceuticals has some characteristics of a very speculative penny stock | |
| The company reported the last year's revenue of 25.19 M. Reported Net Loss for the year was (34.53 M) with profit before taxes, overhead, and interest of 13.65 M. | |
| Zomedica Pharmaceuticals Corp has about 27.4 M in cash with (15.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Zomedica Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Zomedica Pharmaceuticals Corp. Outpaces Stock Market Gains What You Should Know - Yahoo Movies Canada |
Zomedica Pharmaceuticals Returns Distribution Density
The distribution of Zomedica Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Zomedica Pharmaceuticals' future price movements. The chart of the probability distribution of Zomedica Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Zomedica Pharmaceuticals Corp price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Zomedica Pharmaceuticals returns is essential to provide solid investment advice for Zomedica Pharmaceuticals.
| Mean Return | -0.06 | Value At Risk | -7.69 | Potential Upside | 8.33 | Standard Deviation | 5.63 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Zomedica Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Zomedica Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (1.4M) | 61.5M | 133.0M | (167.6M) | (14.4M) | (13.7M) | |
| Free Cash Flow | (16.3M) | (16.3M) | (14.8M) | (12.7M) | (20.6M) | (19.6M) | |
| Other Non Cash Items | 792.1K | 22.1K | 37.7K | 1.5M | 7.5M | 7.8M | |
| Capital Expenditures | 686.9K | 16.8K | 526.2K | 1.0M | 4.6M | 4.9M | |
| Net Income | (19.8M) | (16.9M) | (18.4M) | (17.0M) | (34.5M) | (32.8M) | |
| End Period Cash Flow | 510.6K | 62.0M | 195.0M | 27.4M | 13.0M | 12.3M | |
| Change To Inventory | (2.8M) | 14.0K | 78.6K | (4.0M) | (1.1M) | (1.1M) | |
| Investments | (686.9K) | 1.0M | (71.9M) | (128.8M) | (9.9M) | (10.4M) | |
| Depreciation | 787.6K | 530.0K | 1.1M | 4.0M | 6.3M | 6.6M | |
| Change To Netincome | 3.3M | 1.8M | 6.8M | 7.9M | 9.1M | 9.5M | |
| Change Receivables | (14.0K) | (78.6K) | 211.8K | (617K) | (555.3K) | (527.5K) |
Zomedica Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Zomedica Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Zomedica Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Zomedica stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | -0.14 | |
β | Beta against NYSE Composite | 1.25 | |
σ | Overall volatility | 5.58 | |
Ir | Information ratio | -0.02 |
Zomedica Pharmaceuticals Volatility Alert
Zomedica Pharmaceuticals Corp exhibits very low volatility with skewness of 0.3 and kurtosis of 1.12. Zomedica Pharmaceuticals Corp is a potential penny stock. Although Zomedica Pharmaceuticals may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Zomedica Pharmaceuticals Corp. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Zomedica instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Zomedica Pharmaceuticals Fundamentals Vs Peers
Comparing Zomedica Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Zomedica Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Zomedica Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Zomedica Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Zomedica Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Zomedica Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Zomedica Pharmaceuticals to competition |
| Fundamentals | Zomedica Pharmaceuticals | Peer Average |
| Return On Equity | -0.14 | -0.31 |
| Return On Asset | -0.0741 | -0.14 |
| Profit Margin | (1.37) % | (1.27) % |
| Operating Margin | (1.55) % | (5.51) % |
| Current Valuation | 38.94 M | 16.62 B |
| Shares Outstanding | 979.95 M | 571.82 M |
| Shares Owned By Insiders | 1.59 % | 10.09 % |
| Shares Owned By Institutions | 8.88 % | 39.21 % |
| Number Of Shares Shorted | 63.99 M | 4.71 M |
| Price To Book | 0.55 X | 9.51 X |
| Price To Sales | 5.25 X | 11.42 X |
| Revenue | 25.19 M | 9.43 B |
| Gross Profit | 13.65 M | 27.38 B |
| EBITDA | (25.29 M) | 3.9 B |
| Net Income | (34.53 M) | 570.98 M |
| Cash And Equivalents | 27.4 M | 2.7 B |
| Cash Per Share | 0.19 X | 5.01 X |
| Total Debt | 2.73 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 43.50 X | 2.16 X |
| Book Value Per Share | 0.24 X | 1.93 K |
| Cash Flow From Operations | (15.97 M) | 971.22 M |
| Short Ratio | 11.47 X | 4.00 X |
| Earnings Per Share | (0.04) X | 3.12 X |
| Target Price | 0.44 | |
| Number Of Employees | 144 | 18.84 K |
| Beta | 0.98 | -0.15 |
| Market Capitalization | 126.71 M | 19.03 B |
| Total Asset | 253.2 M | 29.47 B |
| Retained Earnings | (170.93 M) | 9.33 B |
| Working Capital | 90.85 M | 1.48 B |
| Net Asset | 253.2 M |
Note: Insider Trading [view details]
Zomedica Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Zomedica . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.93 | |||
| Day Median Price | 0.13 | |||
| Day Typical Price | 0.13 | |||
| Price Action Indicator | (0.01) | |||
| Period Momentum Indicator | (0.01) | |||
| Relative Strength Index | 83.95 |
About Zomedica Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Zomedica Pharmaceuticals Corp? Buying financial instruments such as Zomedica Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 501.5K | 265K | 172K | 163.4K | Total Assets | 280.4M | 279.6M | 253.2M | 265.9M |
Use Investing Ideas to Build Portfolios
In addition to having Zomedica Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Robots And Drones Thematic Idea Now
Robots And Drones
Large technology companies that are involved in development and manufacturing of drones, robots, or robotic equipment across mechanical engineering, electrical engineering, mathematics and computer science fields. Drones and robotics are projected to significantly grow in demand in the next 5 years. The Robots And Drones theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Robots And Drones Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Zomedica Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Zomedica Stock analysis
When running Zomedica Pharmaceuticals' price analysis, check to measure Zomedica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zomedica Pharmaceuticals is operating at the current time. Most of Zomedica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Zomedica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zomedica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Zomedica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |
Is Zomedica Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.04) | Revenue Per Share 0.026 | Quarterly Revenue Growth 0.192 | Return On Assets (0.07) | Return On Equity (0.14) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.